All Stories

  1. Lifestyle Modulators of Neuroplasticity in Parkinson’s Disease: Evidence in Human Neuroimaging Studies
  2. New Insights into the Relationship between Nutrition and Neuroinflammation in Alzheimer's Disease: Preventive and Therapeutic Perspectives
  3. Variability in Clinical Phenotype in TARDBP Mutations: Amyotrophic Lateral Sclerosis Case Description and Literature Review
  4. Circulating Extracellular Vesicles in Subarachnoid Hemorrhage Patients: Characterization and Cellular Effects
  5. Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)
  6. Real-world use of Safinamide in motor fluctuating Parkinson’s disease patients in Italy
  7. Studies to Assess the Utility of Serum Neurofilament Light Chain as a Biomarker in Chemotherapy-Induced Peripheral Neuropathy
  8. Neuroinflammatory Pathways in the ALS-FTD Continuum: A Focus on Genetic Variants
  9. Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study
  10. Investigating the Prognostic Role of Peripheral Inflammatory Markers in Mild Cognitive Impairment
  11. Plasma Pattern of Extracellular Vesicles Isolated from Hepatitis C Virus Patients and Their Effects on Human Vascular Endothelial Cells
  12. A novel GRN mutation in an Italian patient with non-fluent variant of primary progressive aphasia at onset: a longitudinal case report
  13. Meet the Co-Editor
  14. Isolated Myelopathy in Occult Breast Carcinoma with Negative Paraneoplastic Antibodies: A Case Report of a Rare Condition
  15. The PROB-PD trial: a pilot, randomised, placebo-controlled study protocol to evaluate the feasibility and potential efficacy of probiotics in modulating peripheral immunity in subjects with Parkinson’s disease
  16. Prognostic Role of Visual Evoked Potentials in Non-Neuritic Eyes at Multiple Sclerosis Diagnosis
  17. Relationship between [123I]FP-CIT SPECT data and peripheral CD4 + T cell profile in newly-diagnosed drug-naïve Parkinson’s disease patients
  18. Levodopa Equivalent Dose of Safinamide: A Multicenter, Longitudinal, Case–Control Study
  19. Early Predictors of Disability and Cognition in Multiple Sclerosis Patients: A Long-Term Retrospective Analysis
  20. The Need for Biomarkers in the ALS–FTD Spectrum: A Clinical Point of View on the Role of Proteomics
  21. Neuroimaging in multiple system atrophy
  22. Disease mechanisms as subtypes: Immune dysfunction in Parkinson's disease
  23. COVID-19 Vaccination and Late-Onset Myasthenia Gravis: A New Case Report and Review of the Literature
  24. Visuospatial Deficits are associated with Pisa Syndrome and not Camptocormia in Parkinson's disease
  25. T Lymphocytes in Parkinson’s Disease
  26. Lymphocyte Count and Neutrophil-to-Lymphocyte Ratio Are Associated with Mild Cognitive Impairment in Parkinson’s Disease: A Single-Center Longitudinal Study
  27. PTPA variants and impaired PP2A activity in early-onset parkinsonism with intellectual disability
  28. Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis
  29. Safety of COVID-19 Vaccines: Spotlight on Neurological Complications
  30. A very early onset of juvenile parkinsonism
  31. The Effects of COVID-19-Related Restrictions on Parkinson’s Disease Patients in Italy: Results of a Structured Survey
  32. Early Successful Eye Movement Desensitization and Reprocessing (EMDR) Therapy for Verbal Memory Impairment in an Adjustment Disorder: A Case Report in a Newly-Diagnosed Multiple Sclerosis Patient
  33. Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study
  34. Striatal dopamine transporter imaging in Parkinson’s disease drug-naïve patients: focus on sexual dysfunction
  35. The Role of Tau beyond Alzheimer’s Disease: A Narrative Review
  36. Immune Response Modifications in the Genetic Forms of Parkinson’s Disease: What Do We Know?
  37. The Immune System as a Therapeutic Target for Old and New Drugs in Parkinson’s Disease
  38. Predicting functional impairment trajectories in amyotrophic lateral sclerosis: a probabilistic, multifactorial model of disease progression
  39. Meet the Editorial Board Member
  40. Oxidative Stress in Non-Alcoholic Fatty Liver Disease
  41. Author Correction: Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology
  42. Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis
  43. Susac Syndrome: an uncommon cause of impaired vision
  44. Did the role of the neurologist in the emergency department change during the COVID-19 pandemic? Evidence from an Italian nationwide survey
  45. Contribution of Rare and Low-Frequency Variants to Multiple Sclerosis Susceptibility in the Italian Continental Population
  46. Is There any Link between Madelung Disease and Ischemic Stroke? A Case Report
  47. Clinical relevance of single-subject brain metabolism patterns in amyotrophic lateral sclerosis mutation carriers
  48. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology
  49. Serum Vitamin D as a Marker of Impaired Information Processing Speed and Early Disability in Multiple Sclerosis Patients
  50. Motor and non-motor symptom improvement after mRNA-1273 vaccine in a Parkinson’s disease patient
  51. Guillain–Barrè syndrome following COVID-19 vaccine mRNA-1273: a case report
  52. Increased Prevalence of Neuropsychiatric Disorders during COVID-19 Pandemic in People Needing a Non-Deferrable Neurological Evaluation
  53. Cerebrospinal Tau levels as a predictor of early disability in multiple sclerosis
  54. An Investigation of the Role of Common and Rare Variants in a Large Italian Multiplex Family of Multiple Sclerosis Patients
  55. CSF Tau protein correlates with cognitive impairment in multiple sclerosis patients at diagnosis
  56. Neuromyelitis optica with syringomyelia: A case report and neurosonological follow up
  57. A challenging diagnosis of neurodegenerative dementia: Psychiatric onset of frontotemporal lobar degeneration
  58. The impact of COVID-19 pandemic on cognition of people with dementia
  59. The Impact of SNCA Variations and Its Product Alpha-Synuclein on Non-Motor Features of Parkinson’s Disease
  60. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis
  61. Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19
  62. The Impact of the COVID-19 Pandemic on the Cognition of People with Dementia
  63. Expression of Transcription Factors in CD4 + T Cells as Potential Biomarkers of Motor Complications in Parkinson’s Disease
  64. Polymorphisms of Dopamine Receptor Genes and Parkinson’s Disease: Clinical Relevance and Future Perspectives
  65. Telehealth in Neurodegenerative Diseases: Opportunities and Challenges for Patients and Physicians
  66. A European Observational Study to Evaluate the Safety and the Effectiveness of Safinamide in Routine Clinical Practice: The SYNAPSES Trial
  67. Paraneoplastic neuromyelitis optica spectrum disorders: a case series
  68. Expanding the genetic spectrum of primary familial brain calcification due to SLC2OA2 mutations: a case series
  69. The Yin-Yang of osteopontin in nervous system diseases: damage versus repair
  70. Potential protective role of ACE-inhibitors and AT1 receptor blockers against levodopa-induced dyskinesias: a retrospective case-control study
  71. Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients
  72. Intrathecal kappa free light chains as markers for multiple sclerosis
  73. Genetic parkinsonisms and cancer: a systematic review and meta-analysis
  74. Change over time of COVID-19 hospital presentation in Northern Italy
  75. Relationship between circulating CD4+ T lymphocytes and cognitive impairment in patients with Parkinson’s disease
  76. Kinematic but not clinical measures predict falls in Parkinson-related orthostatic hypotension
  77. CD4 + T‐Cell Transcription Factors in Idiopathic REM Sleep Behavior Disorder and Parkinson’s Disease
  78. Cortical visuomotor interactions in Freezing of Gait: A TMS approach
  79. Correction to: The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson’s disease patients
  80. The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson’s disease patients
  81. Meet Our Editorial Board Member
  82. Nerve conduction, circulating osteopontin and taxane-induced neuropathy in breast cancer patients
  83. Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk
  84. Vogt-Koyanagi-Harada Syndrome: A Case of Bilateral Steroid-Responsive Loss of Vision
  85. Editorial: Peripheral Immunity in Parkinson's Disease: Emerging Role and Novel Target for Therapeutics
  86. Meet Our Editorial Board Member
  87. Meet Our Editorial Board Member
  88. TAM Receptor Pathways at the Crossroads of Neuroinflammation and Neurodegeneration
  89. The vermiform appendix in Parkinson's disease: At the crossroad of peripheral immunity, the nervous system and the intestinal microbiome
  90. Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk
  91. FRI0258 ANTI-RO/SSA POSITIVITY, ANTI-AQUAPORIN4 ANTIBODIES AND CENTRAL NERVOUS SYSTEM INVOLVEMENT: A RETROSPECTIVE STUDY ON A CONTROVERSIAL CORRELATION
  92. Probiotics May Have Beneficial Effects in Parkinson's Disease: In vitro Evidence
  93. Kappa free light chains could predict early disease course in multiple sclerosis
  94. Meet Our Editorial Board Member
  95. K Index is a Reliable Marker of Intrathecal Synthesis, and an Alternative to IgG Index in Multiple Sclerosis Diagnostic Work-Up
  96. Untangling Extracellular Proteasome-Osteopontin Circuit Dynamics in Multiple Sclerosis
  97. Holmes tremor caused by a natalizumab-related progressive multifocal leukoencephalopathy: a case report and brief review of the literature
  98. Ultrasonography Monitoring of Optic Nerve Sheath Diameter and Retinal Vessels in Patients with Cerebral Hemorrhage
  99. Post-lumbar puncture headache: an adverse effect in multiple sclerosis work-up
  100. Exploiting PLGA-Based Biocompatible Nanoparticles for Next-Generation Tolerogenic Vaccines against Autoimmune Disease
  101. Beta2-Adrenoceptor Agonists in Parkinson’s Disease and Other Synucleinopathies
  102. Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy
  103. The Italian multiple sclerosis register
  104. LncRNAs expression profile in peripheral blood mononuclear cells from multiple sclerosis patients
  105. Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk
  106. CSF biomarkers of neurodegeration in early multiple sclerosis course
  107. Parkinson’s disease patients have a complex phenotypic and functional Th1 bias: cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients
  108. LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study
  109. Chronic obstructive pulmonary disease may complicate Alzheimer’s disease: a comorbidity problem
  110. MOG-antibody demyelinating diseases: a case of post-partum severe rhombencephalitis and transverse myelitis
  111. The Length of SNCA Rep1 Microsatellite May Influence Cognitive Evolution in Parkinson’s Disease
  112. Real life evaluation of safinamide effectiveness in Parkinson’s disease
  113. Long non coding RNA expression profile in Peripheral Blood Mononuclear Cells from Multiple Sclerosis patients: potential biomarkers of disease susceptibility and progression
  114. O158 Excessive inhibitory visuomotor connections in parkinson’s disease with freezing of gait
  115. A patient with autoimmune limb-girdle myasthenia, and a brief review of this treatable condition.
  116. Peripheral neuropathy as marker of severe Parkinson's disease phenotype
  117. Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up
  118. The measuring of substantia nigra hyperechogenicity in an Italian cohort of Parkinson disease patients: a case/control study (NOBIS Study)
  119. Role of Anti-Osteopontin Antibodies in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
  120. Extracellular proteasome-osteopontin circuit regulates cell migration with implications in multiple sclerosis
  121. Prevalence and burden of dysautonomia in advanced Parkinson's disease
  122. Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa–Induced Dyskinesia in Parkinson’s Disease
  123. Combined use of Kappa Free Light Chain Index and Isoelectrofocusing of Cerebro-Spinal Fluid in Diagnosing Multiple Sclerosis: Performances and Costs
  124. Insights into the protective role of immunity in neurodegenerative disease
  125. Longitudinal Assessment of Transorbital Sonography, Visual Acuity, and Biomarkers for Inflammation and Axonal Injury in Optic Neuritis
  126. Transorbital Sonography and Visual Outcome for the Diagnosis and Monitoring of Optic Neuritis
  127. Growth Arrest Specific 6 Concentration is Increased in the Cerebrospinal Fluid of Patients with Alzheimer’s Disease
  128. Dopaminergic Receptors on CD4+ T Naive and Memory Lymphocytes Correlate with Motor Impairment in Patients with Parkinson’s Disease
  129. Polymorphisms of dopamine receptor genes and risk of visual hallucinations in Parkinson’s patients
  130. Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia
  131. D NAJC 6 Mutations Associated With Early-Onset Parkinson's Disease
  132. Polymorphisms of dopamine receptor genes are associated to increased risk of visual hallucinations in Italian Parkinson's disease patients
  133. Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases
  134. Thrombin Cleavage of Osteopontin Modulates Its Activities in Human CellsIn Vitroand Mouse Experimental Autoimmune EncephalomyelitisIn Vivo
  135. Impaired visual inhibition in migraine with aura
  136. MRI imaging and clinical features of sciatic nerve injection injury
  137. Peripheral nervous system involvement in Parkinson's disease: Evidence and controversies
  138. Variations of the perforin gene in patients with chronic inflammatory demyelinating polyradiculoneuropathy
  139. Predicting Cognitive Decline in Parkinson’s Disease: Can We Ask the Genes?
  140. Subcutaneous inverse vaccination with PLGA particles loaded with a MOG peptide and IL-10 decreases the severity of experimental autoimmune encephalomyelitis
  141. Intensive Rehabilitation Treatment in Early Parkinson’s Disease
  142. Transorbital Sonography in Acute Optic Neuritis: A Case-Control Study
  143. Joint Congress of European Neurology 31 May–3 June 2014 Istanbul, Turkey
  144. Advances in Neuroimmunology: From Bench to Bedside
  145. Current Understanding on the Role of Standard and Immunoproteasomes in Inflammatory/Immunological Pathways of Multiple Sclerosis
  146. Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens
  147. Revisiting the Molecular Mechanism of Neurological Manifestations in Antiphospholipid Syndrome: Beyond Vascular Damage
  148. Treatment of Chronic Inflammatory Demyelinating Polyneuropathy: From Molecular Bases to Practical Considerations
  149. Evidence of Pre-Synaptic Dopaminergic Deficit in a Patient with a Novel Progranulin Mutation Presenting with Atypical Parkinsonism†
  150. Intensive Rehabilitation Increases BDNF Serum Levels in Parkinsonian Patients
  151. Variations of the UNC13D Gene in Patients with Autoimmune Lymphoproliferative Syndrome
  152. Defining the Epsilon-Sarcoglycan (SGCE) Gene Phenotypic Signature in Myoclonus-Dystonia: A Reappraisal of Genetic Testing Criteria
  153. Robotic gait training is not superior to conventional treadmill training in Parkinson's Disease: A single-blind randomized controlled trial
  154. Discovery and verification of panels of T-lymphocyte proteins as biomarkers of Parkinson's disease
  155. The role of T cell apoptosis in nervous system autoimmunity
  156. Dopaminergic therapies modulate the T-CELL proteome of patients with Parkinson's disease
  157. Rehabilitation improves dyskinesias in Parkinsonian patients: A pilot study comparing two different rehabilitative treatments
  158. Robotic Gait Training Is not Superior to Conventional Treadmill Training in Parkinson Disease
  159. The -346T polymorphism of the SH2D1A gene is a risk factor for development of autoimmunity/lymphoproliferation in males with defective Fas function
  160. The Impact of Osteopontin Gene Variations on Multiple Sclerosis Development and Progression
  161. Cerebrospinal Fluid Biomarkers in Progranulin Mutations Carriers
  162. Expression and genetic analysis of miRNAs involved in CD4+ cell activation in patients with multiple sclerosis
  163. Effectiveness of Intensive Inpatient Rehabilitation Treatment on Disease Progression in Parkinsonian Patients
  164. The Role of Osteopontin in Neurodegenerative Diseases
  165. Fas-mediated T-cell apoptosis in chronic inflammatory demyelinating polyneuropathy
  166. GSK3β genetic variability in patients with Multiple Sclerosis
  167. Progressive multifocal leucoencephalopathy after autologous bone marrow transplantation: a treatment option
  168. Complex pattern of convulsive syncope in glossopharyngeal neuralgia: Video/EEG report and short review
  169. Levodopa‐induced belly dancer's dyskinesias in Parkinson's disease: Report of one case
  170. Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature
  171. Signals of Apoptotic Pathways in Several Types of Meningioma
  172. Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males
  173. Osteopontin is Increased in the Cerebrospinal Fluid of Patients with Alzheimer's Disease and Its Levels Correlate with Cognitive Decline
  174. Progranulin plasma levels as potential biomarker for the identification of GRN deletion carriers. A case with atypical onset as clinical amnestic Mild Cognitive Impairment converted to Alzheimer's disease
  175. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy
  176. FP17-TU-06 Th17, an effector T lymphocyte subset associated with multiple sclerosis (MS) relapses: antigen specificity, cytokine production, and sensitivity to interferon (IFN)-β
  177. Defective Fas-mediated T-cell apoptosis predicts acute onset CIDP
  178. Complex movement disorders in primary antiphospholipid syndrome: A case report
  179. Spontaneous Intracranial Hypotension Presenting as a Reversible Dorsal Midbrain Syndrome
  180. Variations of the perforin gene in patients with multiple sclerosis
  181. Gender-specific influence of the chromosome 16 chemokine gene cluster on the susceptibility to Multiple Sclerosis
  182. MDC/CCL22 intrathecal levels in patients with multiple sclerosis
  183. Candidate gene analysis of SPARCL1 gene in patients with multiple sclerosis
  184. ICOS gene haplotypes correlate with IL10 secretion and multiple sclerosis evolution
  185. CXCL10 haplotypes and multiple sclerosis: association and correlation with clinical course
  186. ICOS cooperates with CD28, IL-2, and IFN-γ and modulates activation of human naïve CD4+ T cells
  187. Fas-mediated T-cell apoptosis is impaired in patients with chronic inflammatory demyelinating polyneuropathy
  188. P-selectin glycoprotein ligand-1 variable number of tandem repeats (VNTR) polymorphism in patients with multiple sclerosis
  189. E-selectin A561C and G98T polymorphisms influence susceptibility and course of multiple sclerosis
  190. Osteopontin gene haplotypes correlate with multiple sclerosis development and progression
  191. Cutaneous silent period in human immunodeficiency virus-related peripheral neuropathy
  192. Abnormal response to glutamate of T lymphocytes from multiple sclerosis patients
  193. Diagnosis of psychogenic paralysis: The role of motor evoked potentials
  194. Anticonvulsvant Drugs and Cognitive Functions in Elderly Patients with Epilepsy
  195. Anticonvulsant Drugs and Cognitive Functions in Elderly Patients with Epilepsy
  196. Defective T cell Fas function in patients with multiple sclerosis
  197. Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer